LAG3 and neoplasm: These mechanisms collectively explain the superior anti-tumor efficacy of the PD-1/LAG-3 bispecific antibody compared with anti-PD-1 and anti-LAG-3 monotherapy or their combination in our in vitro functional studies and in vivo models.